Janssen reports positive clinical data for new psoriasis drug Tremfya

Janssen has announced the findings of a recent phase III clinical trial that demonstrates the safety and efficacy of its new plaque psoriasis therapy Tremfya.

Data from an open-label extension of the VOYAGE 1 trial demonstrated consistent rates of skin clearance with the guselkumab-based treatment over 100 weeks among patients with moderate to severe plaque psoriasis.

More than 80 percent of patients receiving this subcutaneously administered anti-interleukin-23 monoclonal antibody achieved near complete skin clearance and cleared or minimal disease status at week 100, including those initially treated with placebo or the anti-TNF-alpha agent Humira.

Dr Newman Yeilding, head of immunology development at Janssen research and development, said: "We look forward to continued collaborations with regulators as we work to bring Tremfya to patients around the world who may benefit from this novel therapy."

The presentation of these findings comes in the same week that Tremfya was recommended by the European Medicines Agency's Committee for Medicinal Products for Human Use for European regulatory approval.

Janssen previously received US Food and Drug Administration approval of the therapy in July.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.